|
1) Effert PJ, Bares R, Handt S, et al. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J Urol. 1996; 155: 994-8
|
|
|
|
2) Oyama N, Akino H, Suzuki Y, et al. The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer. Jpn J Clin Oncol. 1999; 29: 623-9
|
|
|
|
|
3) Morris MJ, Akhurst T, Larson SM, et al. Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res. 2005; 11: 3210-6
|
|
|
|
|
|
4) Shoder H, Herrmann K, Gonen M, et al. 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res. 2005; 11: 4761-9
|
|
|
|
|
|
5) Yoshimoto M, Waki A, Obata A, et al. Radiolabeled choline as a proliferation marker: comparison with radiolabeled acetate. Nucl Med Biol. 2004; 31: 859-65
|
|
|
|
|
|
6) Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med. 1998; 39: 990-5
|
|
|
|
|
|
7) Tuncel M, Souvatzoglou M, Herrmann K, et al. [11C]choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer. Nucl Med Biol. 2008; 35: 689-95
|
|
|
|
|
|
8) Schiavina R, Scattoni V, Castellucci P, et al. 11C-choline positiron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomogram. Eur Urol. 2008; 54: 392-401
|
|
|
|
|
|
9) Kwee SA, Wei H, Sesterhenn I, et al. Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET. J Nucl Med. 2006; 47: 262-9
|
|
|
|
|
|
10) Igerc I, Kohlfurst S, Gallowitsch HJ, et al. The value of 18F-choline PET/CT in patients with elevated PSA level and negative prostate needle biopsy for localization of prostate cancer. Eur J Nucl Med Mol Imaging. 2008; 35: 976-83
|
|
|
|
|
|
11) Oyama N, Akino H, Kanamaru H, et al. 11C-acetate PET imaging of prostate cancer. J Nucl Med. 2002; 43; 181-6
|
|
|
|
|
|
12) Kotzerke J, Volkmer BG, Neumaier B, et al. Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2002; 29: 1380-4
|
|
|
|
|
|
13) Fricke E, Machtens S, Hofmann M, et al. Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2003; 30: 607-11
|
|
|
|
|
|
14) Oyama N, Miller TR, Dehdashti F, et al. 11C-acetate PET imaging of prostate cancer: detection of recurrence disease at PSA relapse. J Nucl Med. 2003; 44: 549-55
|
|
|
|
|
|
15) Ponde DE, Dence CS, Oyama N, et al. 18F-fluoroacetate: a potential acetate analog for prostate tumor imaging-in vivo evaluation of 18F-fluoroacetate versus 11C-acetate. J Nucl Med. 2007; 48: 420-8
|
|
|
|
|
|
16) Larson SM, Morris M, Gunther I, et al. Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med. 2004; 45: 366-73
|
|
|
|
|
|
17) Kosuda S, Kison PV, Greenough R, et al. Preliminary assessment of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with bladder cancer. Eur J Nucl Med. 1997; 24: 615-20
|
|
|
|
|
|
18) Drieskens O, Oyen R, Van Poppel H, et al. FDG-PET for preoperative staging of bladder cancer. Eur J Nucl Med Mol Imaging. 2005; 32: 1412-7
|
|
|
|
|
|
19) Anjos DA, Etchebehere EC, Ramos CD, et al. 18F-FDG PET/CT delayed images after diuretics for restaging invasive bladder cancer. J Nucl Med. 2007; 48: 764-70
|
|
|
|
|
|
20) Goldberg MA, Mayo-Smith WW, Papanicolaou N, et al. FDG PET characterization of renal masses: preliminary experience. Clin Radiol. 1997; 52: 510-5
|
|
|
|
|
|
21) Park JW, Jo MK, Lee HM. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma. BJU Int. 2008; 103: 615-9
|
|
|
|
|
|
22) Oyama N, Okazawa H, Kusukawa N, et al. 11C-acetate PET imaging for renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2009; 36; 422-7
|
|
|
|
|
|
23) Cremerius U, Wildberger JE, Borchers H, et al. Does positron emission tomography using 18-fluro-2-deoxyglucose improve clinical staging of testicular cancer？－results of a study in 50 patients. Urology. 1999; 54: 900-4
|
|
|
|
|
|
24) De Santis M, Becherer A, Bokemeyer C, et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in ostchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol. 2004; 22: 1034-9
|
|
|
|
|